TY  - JOUR
AU  - Heinrich, Kathrin
AU  - Stintzing, Sebastian
AU  - Weikersthal, Ludwig Fischer von
AU  - Decker, Thomas
AU  - Kiani, Alexander
AU  - Kaiser, Florian
AU  - Al-Batran, Salah-Eddin
AU  - Heintges, Tobias
AU  - Lerchenmüller, Christoph
AU  - Kahl, Christoph
AU  - Seipelt, Gernot
AU  - Kullmann, Frank
AU  - Moehler, Markus
AU  - Scheithauer, Werner
AU  - Jung, Andreas
AU  - Holch, Julian W
AU  - Held, Swantje
AU  - Modest, Dominik Paul
AU  - Heinemann, Volker
TI  - Impact of sex on efficacy and safety of 1st-line treatment with FOLFIRI plus cetuximab or bevacizumab in RAS/BRAF wildtype metastatic colorectal cancer - A subgroup analysis of the FIRE-3 (AIO KRK-0306) trial.
JO  - European journal of cancer
VL  - 232
SN  - 0959-8049
CY  - Amsterdam [u.a.]
PB  - Elsevier
M1  - DKFZ-2025-02670
SP  - 116133
PY  - 2026
AB  - Clinical trials in metastatic colorectal cancer (mCRC) are usually conducted irrespectively of sex. However, differences relating to safety and efficacy in the treatment of mCRC between male and female patients are of growing interest.The randomized FIRE-3 study compared first-line treatment with folinic acid, 5-fluorouracil and irinotecan (FOLFIRI) plus cetuximab to FOLFIRI plus bevacizumab in patients with RAS wildtype (RAS WT) mCRC. The present analysis focusses on the impact of sex and primary tumor (PT) sidedness on outcome parameters.Of 352 patients with RAS WT tumors, 249 (71 
KW  - Anti-EGFR (Other)
KW  - Cetuximab (Other)
KW  - Colorectal cancer (Other)
KW  - Gender (Other)
KW  - Sex (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:41319450
DO  - DOI:10.1016/j.ejca.2025.116133
UR  - https://inrepo02.dkfz.de/record/306677
ER  -